We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > XLRP

News List

Biogen’s inherited eye disease gene therapy misses primary endpoint pharmatimes
May 17, 2021
A gene therapy developed by Biogen for the rare inherited eye disease X-linked retinitis pigmentosa (XLRP) has failed to meet the primary endpoint in a Phase II/III study.
Janssen/MeiraGTx sight loss gene therapy hits targets pharmatimes
July 21, 2020
Janssen has unveiled six-month data from an ongoing Phase I/II trial of its investigational gene therapy for the treatment of inherited retinal disease X-linked retinitis pigmentosa (XLRP).
EMA PRIME status granted to Janssen’s inherited retinal disease gene therapy pharmatimes
March 06, 2020
Janssen has announced that the European Medicines Agency (EMA) has granted both PRIME (PRIority MEdicines) and Advanced Therapy Medicinal Product (ATMP) designations to its adeno-associated virus (AAV)-RPGR gene therapy product ...
Biogen to Acquire Nightstar Therapeutics americanpharmaceuticalreview
March 06, 2019
Biogen has entered into an agreement to acquire Nightstar Therapeutics, a clinical-stage gene therapy company based in London, United Kingdom, which is focused on adeno-associated virus (AAV) treatments for inherited retinal disorders.